Bronchoscopic debulking for endobronchial malignancy: Predictors of recanalization and recurrence.

abstract：:Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non-small cell lung cancer and treated with orally...

journal_title：Thoracic cancer

authors： Luo J,Ni L,Wang M,Zhong W,Xiao Y,Zheng K,Hu P

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable. METHO...

journal_title：Thoracic cancer

authors： Hayakawa D,Takahashi F,Mitsuishi Y,Tajima K,Hidayat M,Winardi W,Ihara H,Kanamori K,Matsumoto N,Asao T,Ko R,Shukuya T,Takamochi K,Hayashi T,Suehara Y,Takeda Nakamura I,Ueno T,Kohsaka S,Mano H,Takahashi K

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by d...

journal_title：Thoracic cancer

authors： Zhang L,Pradhan B,Guo L,Meng F,Zhong D

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

journal_title：Thoracic cancer

authors： Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

更新日期：2020-03-01 00:00:00

abstract：:After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

journal_title：Thoracic cancer

authors： Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

更新日期：2017-07-01 00:00:00

abstract：:The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...

journal_title：Thoracic cancer

authors： Du X,Shao Y,Qin HF,Tai YH,Gao HJ

更新日期：2018-04-01 00:00:00

abstract：:Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...

journal_title：Thoracic cancer

authors： Xu S,Liu X,Liu R,Shi T,Li X,Zhong D,Wang Y,Chen G,Chen J

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...

journal_title：Thoracic cancer

authors： Liu M,Wang X,Li H,Xu L,Jing L,Jiang P,Liu B,Li Y

更新日期：2019-10-01 00:00:00

abstract：:Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...

journal_title：Thoracic cancer

authors： Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda T

更新日期：2020-09-01 00:00:00

abstract：:The main recurrence pattern for lung cancer patients after radical surgery is distant metastasis. The probability of pancreatic metastasis in patients diagnosed with lung squamous cell carcinoma is 0.02%, with a poor prognosis. Chemotherapy is the preferred treatment for recurrence. Single lesions or oligometastasis c...

journal_title：Thoracic cancer

authors： Wang W,Huang C,Wu S,Liu Z,Liu L,Li L,Li S

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

journal_title：Thoracic cancer

authors： Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

更新日期：2020-11-01 00:00:00

abstract：:Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...

journal_title：Thoracic cancer

authors： Fan M,Mo T,Shen L,Yang L

更新日期：2019-07-01 00:00:00

abstract：:Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...

journal_title：Thoracic cancer

authors： Cheng Y,Yu Q,Xiong Y,Guo C,Nie L

更新日期：2021-01-12 00:00:00

abstract：:For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

journal_title：Thoracic cancer

authors： Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND:Uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. METHODS:Eligibility cr...

journal_title：Thoracic cancer

authors： Fukuda M,Suetsugu T,Shimada M,Kitazaki T,Hashiguchi K,Kishimoto J,Harada T,Seto T,Ebi N,Takayama K,Sugio K,Semba H,Nakanishi Y,Ichinose Y

更新日期：2016-07-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD-1)/PD-1 ligand (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do n...

journal_title：Thoracic cancer

authors： Lu M,Zhang L,Li Y,Wang H,Guo X,Zhou J,Duan L,Si X,Xu Y,Zhang L

更新日期：2020-03-01 00:00:00

abstract：:A 60-year-old woman was urgently admitted to our hospital because of vertigo and left hemiplegia. Laboratory examination showed thrombocytopenia, high levels of D-dimer and carcinoembryonic antigen. Brain magnetic resonance imaging (MRI) revealed multiple bilateral cerebral infarctions. Chest computed tomography (CT) ...

journal_title：Thoracic cancer

authors： Nakano Y,Koide N,Koyama Y,Nitta K,Koizumi T

更新日期：2020-12-21 00:00:00

abstract：BACKGROUND:Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for canc...

journal_title：Thoracic cancer

authors： Li S,Sun X,Miao S,Lu T,Wang Y,Liu J,Jiao W

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictiv...

journal_title：Thoracic cancer

authors： Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino T

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...

journal_title：Thoracic cancer

authors： Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

更新日期：2020-10-01 00:00:00

abstract：:Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

journal_title：Thoracic cancer

authors： Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...

journal_title：Thoracic cancer

authors： Zhao D,Han W,Liu X,Cui D,Chen Y

更新日期：2017-07-01 00:00:00

abstract：:A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

journal_title：Thoracic cancer

authors： Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

更新日期：2016-09-01 00:00:00

abstract：BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

journal_title：Thoracic cancer

authors： Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...

journal_title：Thoracic cancer

authors： Tuo L,Sha S,Huayu Z,Du K

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS:Data of patients diagno...

journal_title：Thoracic cancer

authors： Yang Q,Xu Z,Chen X,Zheng L,Yu Y,Zhao X,Chen M,Luo B,Wang J,Sun J

更新日期：2019-04-01 00:00:00

abstract：:Multiple lung nodules caused by pneumonia are a rare presentation in intercostal hemangioma. We experienced a case with intercostal hemangioma that presented with multiple metastasized lung nodules caused by pneumonia, which had previously been misdiagnosed as sarcoma six months earlier. The patient was treated for pn...

journal_title：Thoracic cancer

authors： Mei L,Shi H,Che G

更新日期：2010-11-01 00:00:00

abstract：BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....

journal_title：Thoracic cancer

authors： Zhang X,Kong M,Zhang Z,Xu S,Yan F,Wei L,Zhou J

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:The aim of this study was to explore the influence of image-guided tumor localization modality (Synchrony tracking vs. Xsight spine-based localization) on the local efficacy of CyberKnife treatment in lung cancer and lung metastases. METHODS:Retrospective analysis of 64 patients with pulmonary metastases an...

journal_title：Thoracic cancer

authors： Guo Y,Zhuang H,Zhao L,Yuan Z,Wang P

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:Computed tomography (CT)-guided percutaneous implantation of 125 Iodine radioactive seeds requires the precise arrangement of seeds by tumor shape. We tested whether selecting target areas, including subclinical areas around tumors, can influence locoregional recurrence in patients with non-small cell lung c...

journal_title：Thoracic cancer

authors： Yan WL,Lv JS,Guan ZY,Wang LY,Yang JK,Liang JX

更新日期：2017-05-01 00:00:00